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Abstract
Background: Rett syndrome (RTT), a common cause of mental retardation in girls, is associated with mutations in
the MECP2 gene. Most human cases of MECP2 mutation in girls result in classical or variant forms of RTT. When
these same mutations occur in males, they often present as severe neonatal encephalopathy. However, some
MECP2 mutations can also lead to diseases characterized as mental retardation syndromes, particularly in boys. One
of these mutations, A140V, is a common, recurring missense mutation accounting for about 0.6% of all MeCP2
mutations and ranking 21st by frequency. It has been described in familial X-linked mental retardation (XLMR),
PPM- X syndrome (Parkinsonism, Pyramidal signs, Macroorchidism, X-linked mental retardation) and in other
neuropsychiatric syndromes. Interestingly, this mutation has been reported to preserve the methyl-CpG binding
function of the MeCP2 protein while compromising its ability to bind to the mental retardation associated protein
ATRX.
Results: We report the construction and initial characterization of a mouse model expressing the A140V MeCP2
mutation. These initial descriptive studies in male hemizygous mice have revealed brain abnormalities seen in both
RTT and mental retardation. The abnormalities found include increases in cell packing density in the brain and a
significant reduction in the complexity of neuronal dendritic branching. In contrast to some MeCP2 mutation
mouse models, the A140V mouse has an apparently normal lifespan and normal weight gain patterns with no
obvious seizures, tremors, breathing difficulties or kyphosis.
Conclusion: We have identified various neurological abnormalities in this mouse model of Rett syndrome/X-linked
mental retardation which may help to elucidate the manner in which MECP2 mutations cause neuronal changes
resulting in mental retardation without the confounding effects of seizures, chronic hypoventilation, or other Rett
syndrome associated symptoms.
Background
Rett syndrome (RTT; OMIM #312750) is an X-linked
dominant neurological disorder affecting predominantly
females [1,2] and has an estimated prevalence of 1 in
10,000-15,000 females [3]. In patients with RTT, symp-
toms are generally recognized around 6 to 18 months of
age following an apparently normal period of early
development. Regression of previously acquired skills
and deceleration of head growth are key features of the
disease in conjunction with stereotypic hand move-
ments. Ultimately, affected individuals frequently display
cognitive, social, and language impairments as well as a
variety of serious motor and breathing abnormalities,
seizures, microcephaly, gastrointestinal dysfunction, sco-
liosis, kyphosis, and rigidity [2-4]. Pathological studies of
human RTT cases have shown a reduction in brain size,
and an increase in cell packing density [5,6]. These stu-
dies have also noted a significant reduction in the
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dendritic branching of neurons in specific layers of the
frontal, motor, temporal and limbic cortex [6-9].
Most cases of RTT are caused by point mutations,
insertions, duplications, or deletions in the MECP2
(methyl-CpG binding protein 2) gene [1,4,10]. Over 300
distinct MECP2 mutations have been described and cer-
tain mutations occur with high frequency (T158M,
R168X, R255X, R270X, R294X, R306C, R133C, and
R106W) (IRSA MeCP2 Variation Database, http://
mecp2.chw.edu.au/mecp2/). At least two important
functional domains within the MeCP2 protein have
been identified. The first is a methyl-CpG binding
domain (MBD) which binds specifically to methylated
CpG- dinucleotides and the second is a transcriptional
repressor domain (TRD), which interacts with a tran-
scriptional repressor complex [11,12]. While widely
described in the past as a transcriptional repressor, a
recent report indicates that MeCP2 may also be a tran-
scriptional activator, and may actually function more
often as an activator than a repressor of transcription
[13]. It is also believed to participate in recruiting chro-
matin remodeling and co-repressor proteins [11,12], and
[14]. MeCP2 acts to modulate the transcription of many
genes, one of which, BDNF [13,15,16], is particularly
relevant to diseases causing mental retardation as it is
heavily involved in synaptic plasticity [17] and influences
disease progression in Mecp2 mutant mice [18].
In addition to the classic or variant RTT phenotypes
in females, MECP2 gene mutation has also been
described in males [19-21], sometimes causing a severe
and fatal early onset encephalopathy [22]. One specific
mutation of MeCP2, A140V, does not result in a severe
phenotype or in early lethality. While not resulting in
classical RTT features, this mutation has been reported
to cause X-linked mental retardation (XLMR) and neu-
ropsychiatric syndromes as well as PPM-X syndrome
(OMIM #300055; Parkinsonism, Pyramidal signs,
Macroorchidism, X-linked mental retardation) [23-26].
The A140V mutation is a recurring mutation within the
MBD of MeCP2 accounting for about 0.6% of all
reported MeCP2 mutations (IRSA MeCP2 Variation
Database, http://mecp2.chw.edu.au/mecp2/). This muta-
tion was first reported in a female with mild mental
retardation, her daughter with mild mental retardation,
and her four sons with severe mental retardation [23].
In a cohort of mentally retarded patients negative for
expansion of the CGG repeat at the FMR1 locus, Cou-
vert et al found two sporadic cases of A140V mutation
[21]. A three-generation family with five affected males
(MRX 79) was shown to carry the A140V mutation [26].
The A140V mutation has also been reported in a young
boy with language disorder and schizophrenia [27]. In
addition to the previously listed symptoms, dysarthric
speech, mild dysmorphic features, spasticity, gait
abnormalities, mild microcephaly, trophic changes of the
legs, distal atrophy in the limbs, kyphoscoliosis, ankle
clonus, and abnormal deep tendon reflexes are also
symptoms associated with this mutation [23]. Thus, the
A140V MeCP2 mutation is an important cause of
XLMR and developmental disorders and is somewhat
distinct clinically from classic RTT.
It has been predicted based on structural data that the
A140V mutation, located in the a1 helix of the MBD,
could potentially affect the structure of the MeCP2
MBD and therefore the methyl-CpG DNA binding func-
tion. Ohki, et al. [28] speculate that due to its bulky side
chain, the substituted valine may cause reduced DNA
binding affinity and Orrico, et al., [25] using secondary
structure prediction programs, proposed that the A140V
mutation shortens the a1 helix by half, potentially
resulting in an alteration of function. Although many
MECP2 gene mutations do affect the methyl-CpG DNA
binding function of the MeCP2 protein, the A140V
mutation has been reported not to, despite predictions
based on its location within that functional domain [29].
Indeed, MeCP2 A140V protein localizes to heterochro-
matic foci, containing abundant methyl- CpG sites, as
efficiently as wild type (WT) MeCP2. In addition, DNA
binding assays in cultured cells have demonstrated that
the A140V mutation does not affect binding to methy-
lated DNA [29,30]. Nevertheless, another interesting
property of MeCP2 A140V protein was discovered in
studies of transcriptional activity in transfected cells.
MeCP2 A140V repressed transcriptional activity from
methylated promoters at levels comparable to WT and
from unmethylated promoters at a level approximately
40% higher than WT MeCP2 [30]. This raises the possi-
bility that higher repressive activity by MeCP2 A140V
may affect the normal expression of unmethylated
genes.
The A140V mutation is also reported to directly affect
the ability of MeCP2 to bind to the ATRX protein [29],
a helicase/ATPase believed to be involved in chromatin
remodeling [22]. Alpha-thalassemia X-linked mental
retardation syndrome (ATRX; OMIM #301040) is
caused by mutation of the ATRX gene. In addition to
the hematologic abnormality alpha-thalassemia, ATRX
gene mutations also result in mental retardation, micro-
cephaly, dysmorphic features, genital and renal abnorm-
alities, growth deficiency, seizures, spasticity,
gastrointestinal dysfunction, and kyphoscoliosis and
other skeletal abnormalities [31-34]. Many of the symp-
toms of ATRX overlap those seen in patients with a
classic RTT mutation of the MECP2 gene. There are
also clear differences, the presence of dysmorphic fea-
tures in ATRX mutations for example. Interestingly, the
A140V mutation reproduces symptoms of both condi-
tions while still being somewhat distinct from each of
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them. This may provide a glimpse into the mechanism
underlying each of these conditions. Currently there are
no complete ATRX knock out mouse models due likely
to the described embryonic lethality in males [35]. Tis-
sue specific conditional inactivation of ATRX results in
enhanced cell death during corticogenesis with early
lethality (forebrain specific inactivation) [36] and inter-
neuron defects in the retina (retina specific inactivation)
[37].
A variety of mouse models of RTT have been pre-
viously developed and tested. One of the first Mecp2
mutant mouse models generated lacked exons 3 and 4.
This model demonstrated that MeCP2-null animals
were viable and did not have a specific initial phenotype.
Between the ages of 3 and 8 weeks these animals (null
males) developed abnormalities of gait and breathing,
ultimately leading to early death at around 2 months of
age [38]. A second MeCP2-null mouse was generated by
deletion of Exon 3. Male mice appeared healthy for the
first few weeks of age but developed abnormal move-
ments, motor control, and breathing by 5 weeks of age
with death occurring around 10 weeks. Female mice in
this study exhibited similar symptoms but with a time
course delayed by months [39].
Shahbazian et al. [40] generated mice with truncation
of the C-terminal third of the coding region (308/y
mouse) by introducing a stop codon following amino
acid 308, which is located at the C terminal end of the
transcriptional repressor domain. Male mutant mice
survived to at least 1 year of age and developed a variety
of symptoms including tremor, myoclonic seizures,
kyphosis and stereotyped forelimb movements. The
motor performance of these mice declined with age.
Histological studies of the brain were normal and fear
conditioning and spatial learning were normal, however,
the mice did display enhanced anxiety and an abnormal
corticosterone stress response [41]. Recently, a knock-in
model of RTT (R168X) was generated, reproducing a
common non-sense mutation of MeCP2 found in
human cases. As with other RTT model mice, male
R168X mice die early at around 12 weeks of age, but
display symptoms suggestive of RTT such as breathing
irregularities, hypoactivity, and hind limb atrophy and
clasping. Female heterozygous mice show similar symp-
toms but not until around 6 months of age [42]. As
reported in pathological studies of human RTT brain
tissues [5,6], abnormalities of brain size [39,43] and cell
packing density have been observed in mouse models of
RTT [39,44,45]. Abnormalities of dendrite branching
have also been reported in some Rett syndrome mouse
models [44,45]. Much of the testing in mouse models
has been done using hemizygous males to avoid the
phenotype variability resulting from random X inactiva-
tion in females, which is considered to influence
phenotype in human RTT patients. We have performed
our initial tests in males for this reason and because
A140V is more commonly recognized in longer surviv-
ing male patients.
The pathogenesis of the neurological phenotype in
RTT remains unclear, and continued study of mouse
models will improve our understanding. The various
mouse models recapitulate the symptoms of RTT in
many ways but are often distinct from each other.
Although much has been learned about RTT through
the study of existing mouse models, the A140V model
we have created is unique. It reproduces a recurring
missense mutation seen in humans and, in males,
results in an XLMR phenotype (rather than classical
RTT). In addition, due to the long life span of mutant
male mice, developmental studies can be performed.
We expect that by a careful analysis of the A140V
mouse, we will better understand the important roles
that MeCP2 plays in the pathogenesis of developmental
brain disorders that result in mental retardation. Here
we describe the construction and initial characterization
of brain abnormalities in the MeCP2 A140V mutant
mouse model of RTT/XLMR. In addition to being a
model for these two diseases, the A140V mutant mouse
permits the study of a novel mechanism by which
MeCP2 mutation might affect neural development; its
interaction with the ATRX chromatin remodeling
protein.
Results
Generation of the MeCP2 A140V mutant mouse
The A140V mouse model of RTT/XLMR was generated
by introducing a point mutation (a C to T change at
nucleotide position 601 of the MeCP2-e2 mRNA, NCBI
Reference Sequence: NM_010788.3) that results in the
A140V missense mutation of MeCP2 protein. The WT
locus, targeting vector, and recombined locus, are dia-
grammed in Figure 1A; also shown in Figure 1A is the
location of Probe A (external to the targeting vector)
used for Southern blot analysis as well as the Southern
blot Bam HI fragments. In addition, the location of the
genotyping primers (F30/B34) is indicated. Results of a
PCR based test of ES cell DNA to detect homologous
recombination at the 3’-end of the targeting vector are
shown in Figure 1B (Upper Panel). The WT allele yields
a 322 bp fragment while the mutant allele yields a 362
bp fragment. As a confirmatory test these fragments
were digested with Acl I which cuts the mutant allele
but not the WT allele, yielding a double band of 227 bp
and 135 bp (Figure 1B Lower Panel). Southern blot ana-
lysis of Bam HI digested ES cell DNAs detects a 5.5 kbp
band, confirming homologous recombination at the 5’-
end of the targeting vector (Figure 1C). ES cell clones
that were positive by PCR (3’-end) and Southern blot
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(5’-end) were then sequenced to verify that they were
hemizygous for the A140V mutation (data not shown)
and two of these clones were used for blastocyst injec-
tion. Shown in Figure 1D are PCR genotyping results of
F1 females: heterozygous females produce two bands
and WT females produce a single (smaller) band. Plas-
mid controls show either the single smaller band (WT)
or single larger band (mutant). A chimeric male created
from the 177U9 ES cell clone was used to produce het-
erozygous female founders for the MeCP2 A140V
mouse colony.
Mutant Mecp2 mRNA is expressed in brain tissue
We confirmed that only mutant Mecp2 mRNA was pre-
sent in brain tissue of male hemizygous animals by
reverse transcription PCR (RT-PCR). cDNA was pre-
pared from cerebellar total RNA extracted from male
animals (2 A140V mutant and 2 WT controls), and
tested by PCR (with primers F30 and B34, located
within the 3’-UTR). As shown in Figure 2A (Left Panel)
mutant animals display only the larger fragment while
WT animals display only the smaller fragment. This
result also confirms the presence of the Mecp2 3’-UTR.
Figure 1 Generation of the MeCP2 A140V “knock-in” mouse. (1A) Diagram showing the WT Mecp2 locus, the A140V targeting vector, and
the recombined MeCP2 A140V locus used to create the knock-in mouse. (1B) PCR demonstrating ES cell DNA positive (177U9, W7, and A6) and
negative (G3) for homologous recombination at the 3’ end of the targeting vector. Lanes “WT” and “Mut” are plasmid DNA controls
demonstrating the WT and A140V mutant PCR fragments (Upper Panel). The PCR fragments were digested with Acl I which cuts only the
mutant PCR fragments, confirming the presence of the A140V mutation and producing a double band (1B Lower Panel). (1C) Southern blot
analysis Bam HI digested ES cell DNA. A 5.5 kilobase pair (kbp) band was detected confirming homologous recombination at the 5’ end of the
targeting vector. The ladder on the left is in kbp. (1D) PCR genotyping results of F1 generation females. DNA from a WT female produces a
single band while DNA from a heterozygous female (Het) produces two bands. The WT and Mut lanes show control plasmid reactions.
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A different segment of cerebellar Mecp2 cDNA (one
that includes the A140V site) was then amplified to con-
firm that there was no genomic DNA contamination of
the cDNA used in these tests. Samples from both WT
and mutant animals showed only the cDNA band
(shown) and not a larger genomic DNA band (data not
shown), thus the cDNA samples were free of genomic
DNA contamination (Figure 2A Right Panel). Sequen-
cing performed on purified cDNA from these bands
confirmed the A140V mutation (data not shown).
MeCP2 protein is expressed in the brain of A140V
mutant animals
As this is not a knock-out or truncating model, it was
expected that the full length MeCP2 protein would be
present in the brains of hemizygous male mice. Immu-
nostaining in brain slices using an anti-MeCP2 antibody
directed against the C-terminus of the protein demon-
strated the presence of the MeCP2 protein in the brain
tissue of hemizygous mice as well as wild type control
mice (Figure 2B). A peptide blocking assay confirmed
the specificity of the antibody (data not shown). The
mutation does not appear to have affected the nuclear
or brain regional distribution of MeCP2 protein.
Mecp2 mRNA levels in wild-type and A140V mouse
cerebellum by qRT-PCR
Total RNA was extracted from the cerebellum of three
A140V male mice and three WT male littermates (6
months of age). Quantitative real time PCR (qRT-PCR)
reactions were performed using PCR assays for Mecp2
and Gapdh from SA Biosciences (Frederick, MD). The
primer set for Mecp2 detects both the e2 and e1 iso-
forms of Mecp2. Figure 3 shows data graphs for Mecp2
and Gapdh (qRT-PCR and melting curves) (3A) as well
as a table of Ct (cycle threshold) values including mean
and standard deviation (in parentheses), and ΔCt used
in the calculation of fold change (F) in mRNA levels,
comparing A140V to WT (3B). Fold change between
mutant and wild-type is calculated using the ΔΔCt
method (F = 2 exp [- (ΔCt.mutant - ΔCt.wild-type)]). In
the cerebellum, fold change in Mecp2 mRNA levels
(A140V: WT; normalized to Gapdh levels) was 0.91 (p =
0.7043). This demonstrated that in the cerebellum of
WT and mutant 6 month old animals we were unable
to detect a significant difference in the abundance of
WT and mutant steady state Mecp2 mRNA (respec-
tively). This suggests that the A140V mutation does not
significantly affect transcription or mRNA stability.
There are no obvious phenotypic abnormalities of the
A140V mice
No obvious phenotypic differences between A140V and
WT male mice were noted. Somatic growth between 6
and 18 weeks of age in mutant animals was similar to
WT controls (Figure 4). We have not observed abnorm-
alities in body morphology (such as kyphosis) in animals
observed up to 14 months of age. Necropsy of mutant
animals has not revealed any gross organ pathology. No
seizures or tremors have been observed in these animals.
Female heterozygous mice displayed a normal level of
fertility although attempted breedings of male hemizy-
gous mice have thus far been unsuccessful. Both male
hemizygous and female heterozygous A140V mice have
lived to greater than 14 months of age with no unusual
health issues.
Increase in cell packing density in mutant animals
We compared histological sections of brain tissue from
5 month old WT and A140V male mice (Cresyl violet
staining). Although the WT and A140V sections were
processed together, there was an apparent increase in
staining intensity in the A140V mutant tissues. On
Figure 2 Mecp2 mRNA and protein are present in the brains of
A140V mutant male mice. (2A) Total RNA was extracted from the
cerebella of mice and used for cDNA synthesis. RT-PCR confirmed
the presence of Mecp2 mRNA in the cerebella of 2 WT and 2 A140V
(Mut) mice (Left Panel). The mutant mRNA species results in a larger
fragment by PCR than the WT mRNA species. A second RT-PCR
reaction amplifying a different segment of the cDNA containing the
A140V mutation site confirmed that there was no contamination of
the total RNA used for the cDNA synthesis with genomic DNA. WT
and A140V (Mut) cDNA showed only the presence of a band of the
correct size for cDNA PCR product (Right Panel). (2B)
Immunohistochemistry on frozen brain slices demonstrates the
presence of MeCP2 protein in the brain of an A140V hemizygous
mouse. Staining in the hippocampus and the cerebellum are similar
in the WT and A140V mice using an antibody recognizing the C-
terminus of MeCP2. Scale bars are 200 μm.
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Figure 3 Mecp2 mRNA levels are similar in WT and A140V mouse cerebellum by qRT-PCR. (3A) Quantitative real time PCR (qRT-PCR)
reactions were performed using PCR assays for Mecp2 and Gapdh. qRT-PCR data graphs (Upper Panels) and melting curves (Lower Panels) for
Mecp2 and Gapdh are shown. (3B) A table of Ct (cycle threshold) values is shown including mean and standard deviation (in parentheses) and
ΔCt used in the calculation of fold change (F) in mRNA levels. F (Mecp2:Gapdh) = 0.91.
Figure 4 MeCP2 A140V male mice show similar somatic growth patterns to WT controls. Male WT and MeCP2 A140V mice were weighed
weekly between the ages of 6 and 18 weeks. No significant difference was found between the mean weights of the two groups. Error bars
indicate one standard deviation.
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closer examination, it became apparent that this was
due to an increase in the packing density of cells in the
mutant animals. This increase in packing density was
noted in the frontal cortex and olfactory bulbs (Figure
5A and 5B), in the dentate gyrus and regions CA1, CA2,
and CA3 of the hippocampus (Figure 6A and 6B), and
in the granule cell layer of the cerebellum (Figure 7).
The difference in cell packing density between A140V
and WT male mice was quantified by counting all nuclei
in a standard volume of tissue (80 mm3) from the cere-
bellar granule cell layer (Figure 8). This analysis demon-
strated that there is a significantly higher (p < 0.05)
density of cell nuclei in the A140V cerebellar granule
layer than in WT controls.
Abnormal dendritic branching in mutant cortical neurons
Qualitative abnormalities of dendritic branching were
noted upon initial visualization of various regions of
Golgi-Cox stained cortical tissue from MeCP2 A140V
mice. An extended focus (compressed Z-stack) image
of the visual cortex is shown as an example (Figure 9).
In order to begin to evaluate neuronal dendritic struc-
ture in the A140V mouse, Scholl analysis [46] was
performed on layer II/III pyramidal neurons of the
somatosensory cortex. This analysis was done using
Scholl analysis on brightfield Z stack images of Golgi-
Cox stained neurons in order to analyze the full arbors
of both the apical and basal dendrites. A diagram of
this adaptation of the Scholl analysis technique is
shown in Figure 10. Male A140V and wild type mice
2-3 months old were used for this analysis. This quan-
titative analysis demonstrated significant differences in
the branching complexities of the dendritic arbors of
these neurons. Apical dendrites showed very signifi-
cant differences in branching at 80 and 100 μm dis-
tances from the cell body and basal dendrites showed
significant differences at 40, 60, and 80 μm (Figure
11A and 11B).
Figure 5 Increases in cell density were found in the frontal cortex and olfactory bulbs of MeCP2 A140V mice. Brain slices from WT and
A140V male mice were stained with cresyl violet. Shown are areas of the frontal cortex (A) and olfactory bulbs (B). Arrows indicate areas of
increased cell density. Scale bars are 500 μm.
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Discussion
The A140V mouse model was constructed in order to
more closely examine the mental retardation associated
with RTT. This was expected to be a mental retardation
model in mice due to the effects of this mutation in
human male patients. Male patients with the A140V
mutation survive into adulthood, indicating that this
mutation is less likely to compromise functions essential
for life. However, significant mental retardation is com-
mon in males carrying this mutation while carrier
females show mild or no symptoms [23-26]. The A140V
mutation is predicted to be non-truncating and this was
verified by immunoflourescence staining of brain slices
from WT and MeCP2 A140V male mice. The staining
was performed with a C-terminal MeCP2 antibody to
demonstrate that the MeCP2 protein was not truncated
by the A140V mutation.
The initial characterization of the MeCP2 A140V
mouse has revealed some interesting abnormalities.
During casual observation the mice appear normal with
no variation in weight or body morphology and no indi-
cations of seizures or tremors. However, there are cellu-
lar abnormalities in the brain consistent with those seen
in RTT syndrome and other diseases resulting in mental
retardation. An increase in cell packing density was
apparent upon histological studies of brain tissue from
the mutant animals. Qualitative differences in cell den-
sity in the cerebellum were confirmed by performing
cell counts. The results of these cell counts showed sta-
tistically significant differences in cell density. Increased
cell packing density has been previously noted in both
human RTT patients [5] and in RTT mouse models
[39,44,45]. The MeCP2 null mouse created by deletion
of exon 3 revealed increases in cell density in the hippo-
campus, cerebral cortex, and cerebellum that closely
parallel our own results [39]. A study of the brains of
three RTT patients found an increase in cell-packing
density in multiple brain regions including the cerebral
Figure 6 Increases in cell density were found in the hippocampus and dentate gyrus of MeCP2 A140V mice. Panel A shows cresyl violet
stained hippocampi from WT and A140V mice. Staining is darker in the A140V mice due to an increase in cell density. Scale bar is 500 μm.
Panel B contains enlargements of the CA1, dentate gyrus and CA2/CA3 regions of the hippocampi more clearly demonstrating the increase in
cell density seen in Panel A. Scale bars in the enlarged images indicate 100 μm.
Jentarra et al. BMC Neuroscience 2010, 11:19
http://www.biomedcentral.com/1471-2202/11/19
Page 8 of 15
cortex, basal ganglia, thalamus, hippocampus, and amyg-
dala. Abnormalities were also reported in the cerebellum
although an increase in cell packing density was not
reported [5].
We find no previous descriptions of cell density
abnormalities in the olfactory bulbs of Rett mouse mod-
els. We are uncertain if this is because cell density
abnormalities have not previously been seen in olfactory
bulbs or if the olfactory bulbs were not examined in
these mice. There have been reports of defects in neuro-
nal development in olfactory neurons from the nasal
epithelium of RTT patients [47]. In addition, defects of
olfactory neuron maturation and protein expression
have been found in two previously described RTT
mouse models [48-51], indicating that olfactory defects
are not unusual in RTT or in RTT mouse models. In
addition, a recent and very thorough study of brain
morphology found changes in the volume and shape of
Figure 7 Increases in cell density were found in the cerebellum of MeCP2 A140V mice. Left panels show low power images of cresyl
violet stained cerebelli from WT and A140V mice. The A140V cerebellum has noticeably darker staining due to an increase in cell density. Scale
bar is 500 μm. Right panels show enlargement of these images demonstrating the differences in cell density. Scale bar is 100 μm. Arrows
indicate areas of increased cell density.
Figure 8 Quantitative analysis of cell density in the cerebellum of MeCP2 A140V mice. Cresyl violet stained cell nuclei in cerebellar
sections from WT and A140V mice were counted in two separate areas of the granule cell layer in the cerebellum. In each cerebellar area, three
adjacent regions were counted and the mean taken. The means for each area for each genotype are shown on the bar graph. The differences
between the means were significant, (*) p < 0.05, indicating an increase in cell density in the A140V cerebellum.
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olfactory bulbs in two MeCP2 null mouse models [43].
We have seen abnormalities in the shape of olfactory
bulbs and the morphology of glomeruli in some the
A140V male hemizygous mice although this has not
been quantified and will be the subject of further study.
A lack of branching complexity in cortical pyramidal
neurons in many brain regions has been reported in
human cases of RTT [6-9] as well as in mouse models
[44,45]. In fact, dendritic branching anomalies are often
found in conjunction with mental retardation of many
causes [52,53]. The A140V mutation is strongly asso-
ciated with mental retardation [23-26]; therefore, we felt
that abnormal dendritic branching patterns of neurons
would likely occur in this new mouse model. We
explored the branching complexity of neurons in the
A140V mouse model and found differences between
WT and MeCP2 A140V mice. We noted significant dif-
ferences in the branching complexity of both the apical
and basal dendrites of layer II/III pyramidal neurons of
the somatosensory cortex as measured by Scholl analy-
sis. This correlates closely with other reports of
decreases in branching complexity of cortical pyramidal
neurons in tissue from both human RTT patients and in
Mecp2 mutant mouse models. We also found apparent
differences in branching complexity in the visual cortex
although this has not yet been quantified.
The MeCP2 A140V mouse has proven to be distinct
from other mouse models of MeCP2 mutation. Like its
human counterpart, the A140V mutation in mice pro-
duces symptoms both correlating with and disparate
from the classical symptoms of RTT. In humans, the
A140V mutation causes a mental retardation syndrome
that has associated with it abnormalities of gait, kyphos-
coliosis, mild microcephaly, spasticity, dysarthric speech,
and occasionally mental illness such as schizophrenia
[21,23,26,27]. However certain features of classic Rett
syndrome such as stereotypic hand movements, breath-
ing abnormalities and seizures [2,3] are notably absent
Figure 9 Qualitative abnormalities of neuronal dendritic branching were seen in the layer II/III pyramidal neurons of the visual cortex
of MeCP2 A140V mice. Extended focus images of Golgi-Cox stained brain sections from WT and A140V mice are shown. Arrows indicate areas
of apparent decreased dendritic branching in the A140V mouse in comparison to the WT mouse. Scale bar is 100 μm.
Figure 10 The Scholl analysis technique for assessing dendritic
complexity was adapted for use in brightfield Z-stack images
of Golgi-Cox stained neurons. The diagram shows an illustration
of Scholl lines superimposed at 20 μm increments on a Z-stack of
images of a stained neuron. This was done using Zeiss AxioVision
software. Each Z-stack image is separated by only 0.280 μm
allowing all dendritic intersections with Scholl lines to be clearly
seen and counted. Drawing not to scale.
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in humans with the A140V mutation. These distinctions
suggest that the A140V mutation affects certain func-
tions of the MeCP2 protein while preserving others.
There is for instance the report indicating that the
MeCP2 A140V protein has an increased binding affinity
for unmethylated DNA [30], the functional conse-
quences of which are unknown. There is also the inter-
esting finding that although the A140V mutation
preserves the methyl-CpG binding function of MeCP2 it
does interfere with binding to the mental retardation
associated protein ATRX [29]. This raises the possibility
that disruption of the MeCP2-ATRX interaction is in
someway related to the neurological symptoms that
occur in both humans with the A140V mutation and in
our engineered mice.
ATRX is chromatin remodeling protein that is a
SWI2/SNF2 DNA helicase ATPase that is the cause of
ATRX syndrome [33]. This protein has only recently
been identified as a binding partner of the MeCP2 pro-
tein. Analysis of brain tissue from MeCP2-null mice
revealed that loss of MeCP2 in mature neurons leads to
delocalization of the ATRX protein, suggesting that
MeCP2 may be required for the proper localization of
ATRX. In vitro studies done using fusion proteins in
mouse fibroblasts revealed that the MeCP2 A140V pro-
tein, while properly localized to heterochromatin within
the nucleus, fails to recruit ATRX to the heterochroma-
tin. In contrast, WT MeCP2 protein efficiently recruits
ATRX to heterochromatin [29]. This failure to localize
ATRX to heterochromatin may be important in under-
standing the normal function of both the MeCP2 and
ATRX proteins.
We believe that it is important to note that the mice
used in these experiments belong to early generations
(F1 to F4) and are therefore in a mixed 129X1/S1 and
C57BL/6 background. In addition, the neomycin resis-
tance gene cassette used in the construction of these
mice has not been excised from the experimental ani-
mals although we have begun production of a line of
mice in which the neo cassette has been removed. As
Figure 11 Dendritic complexity of pryamidal neurons in the somatosensory cortex is decreased in MeCP2 A140V mice. Scholl analysis
was performed on Z-stack images of Golgi-Cox stained layer II-III pyramidal neurons from the somatosensory cortex of WT and A140V mice.
Panel (A) shows the results of analysis of apical dendrites. Panel (B) shows the results of analysis of basal dendrites. Error bars indicate one
standard deviation. (**) p < 0.01 (***) p < 0.001
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genetic background and the presence of extra DNA
sequences such as the neo cassette can contribute to
phenotype we will be repeating these experiments in
later generation mice lacking the neo cassette in order
to confirm our experimental results. However, we
believe that, given the close parallels of our data with
that seen in other mouse models of Mecp2 gene disrup-
tion, the phenotype we have observed is in fact due to
the A140V mutation itself.
Conclusions
We believe that this new mouse model will provide
insight into the functions of MeCP2, including its asso-
ciation with the ATRX protein. The A140V mouse has
proven to reproduce some of the abnormalities of other
Mecp2 mouse models (increased cell packing density
and decreased neuronal dendritic arbors) while failing to
reproduce others (seizures, tremors, kyphosis, breathing
abnormalities, shortened life span). With this knowledge
we can continue dissecting the functions of MeCP2 in
the hopes of explaining its relationship to mental retar-
dation and other clinical symptoms.
Methods
Generation of A140V “knock-in” mice
Breeding protocols and all animal experiments were
approved by the Institutional Animal Care and Use
Committee (IACUC) of St. Joseph’s Hospital and Medi-
cal Center. An 11 kbp Bam HI fragment of the mouse
MeCP2 gene, that included exon 3 and part of exon 4,
was isolated by restriction digestion of a BAC clone
(mBAC B22804). The 5’- end of the insert was first
trimmed by restriction digestion with Pml I. A pGK-
Neo cassette (flanked by two Frt sites and a single LoxP
site, gift of Dr. Dymecki (Department of Genetics, Har-
vard Medical School), was inserted into the Nde I site
located about 1.7 kbp upstream of exon 3. A second
LoxP site and a novel Acl I restriction were inserted
into the 3’-UTR of exon 4 (into an Mfe I site located
about 400 bp downstream of the translation termination
codon). A single base mutation was introduced using
the QuikChangeXL kit (Stratagene Inc., Cedar Creek,
Texas): a C to T change at nucleotide position 601 of
the Mecp2-e2 mRNA, resulting in the A140V missense
mutation. Pml I linearized targeting vector was electro-
porated into the R1 line of ES cells [54] (male genotype,
Strain 129X1/S1) under previously described conditions
[55]. G418 (neomycin analogue) resistant clones were
tested for proper recombination at the 3’-integration site
by a PCR based assay using the following primers:
F30: 5’ CGACAAGCACAGTCAGGTTGAAGAC 3’
B34: 5’ TCCCAAGAGTCCCATAGTTTCTCC 3’
The wild-type allele yields an amplimer that is 322 bp
long, while the mutant allele yields an amplimer that is
362 bp long. Random integration of the targeting vector
into the mouse genome results in both wild-type and
mutant bands. The PCR product was also digested with
Acl I, which cuts the mutant amplimer into two seg-
ments (227 bp and 135 bp), leaving the wild-type ampli-
mer uncut. Selected ES clone DNAs were tested by
Southern blot for correct recombination at the 5’end,
using Probe A. Homologous recombination at the 5’
end results in a 5.5 kbp band, and clones that retain the
wild-type locus produce an 11 kbp band. Finally,
selected positive ES cell clones were verified by sequen-
cing to confirm the presence of the desired point muta-
tion. Two ES cell clones (169J6 and 177U9) were then
injected into blastocysts from C57BL/6 mice (done
under contract by Ingenious Targeting Laboratories,
Inc., Stony Brook, New York) and implanted into
pseudo-pregnant females. Male chimeras were harem
bred with wild-type C57BL/6 mice and tail DNAs from
all female F1 pups were tested for the presence of the
transgene. Founder females (derived from ES clone
177U9) were identified by PCR, Southern blot, and
DNA sequencing. These founder females were used to
establish our colony of A140V mice by backcrossing
with WT C57BL/6NCrL male mice (Charles River, Wil-
mington, Massachusetts), yielding mutant hemizygous
males, heterozygous females, and WT controls. Hetero-
zygous females produced in the colony were back-
crossed with WT C57BL/6NCrL male mice to produce
experimental mice as well as additional breeding stock.
MeCP2 RT-PCR
Total RNA was extracted from the cerebella of 2 mutant
and 2 WT male mice and treated with DNase I to
remove traces of genomic DNA. cDNA was synthesized
using random hexamers (Superscript III kit, Invitrogen,
Inc., Carlsbad, California). cDNA from each of these
four animals was used in PCR reactions with the F30
and B34 primers described above. The amplimer from
mutant animals is 40 bp larger than the amplimer from
WT animals. A second cDNA fragment (729 bp) that
included a portion of exon 3 and exon 4, containing the
A140V point mutation was then amplified using the fol-
lowing primers:
U256 (located within exon 3): 5’ GTATGATGACCC-
CACCTTGC 3’
L1452 (located within exon 4): 5’ TTCAGTCCC-
TTCCCGCTTTT 3’
The cDNA amplimers from WT and mutant RNAs
were gel purified and sequenced to verify WT or mutant
status at the codon for amino acid 140. When genomic
DNA was used as a template for PCR using these same
primers, the amplimer was 1216 bp long (providing a
control for contamination of the RNA by genomic
DNA).
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qRT-PCR
Total RNA was extracted from cerebella of three mutant
male mice and three WT male littermates (6 months
old) using Trizol (Invitrogen, Inc., Carlsbad, California)
and cleaned up using an RNA extraction kit (SA Bios-
ciences, Frederick, MD). First strand cDNA was synthe-
sized (kit from SA Biosciences) and used in qRT-PCR
reactions using PCR assays and SYBR Green master mix
from SA Biosciences (Mecp2, cat no. PPM31215E, and
Gapdh, cat no. PPM02946E). Controls were first done
with mouse reference RNA to verify comparable effi-
ciency of PCR reactions, and negative controls included
no-reverse transcriptase (NRT) reactions for each RNA.
Triplicate reactions were done for each primer assay
and each of the 6 cDNA samples. Threshold level of
fluorescence was set across the entire run within the
exponential phase of amplification. The corresponding
Ct values were then determined for each sample in the
run. The means, standard deviations, and p value were
calculated using GraphPad InStat3 software.
Histology: Cresyl Violet Staining of Brain Tissue
Mice were anesthetized and transcardially perfused with
saline followed by 4% buffered paraformaldehyde (PFA).
The brains were then post-fixed in 4% PFA overnight at
4°C and then cryoprotected in 30% sucrose for 1-2 days.
Subsequently, brains were frozen in an isopentane/dry
ice bath. The brains were immediately sectioned into 30
μm slices using a cryostat, slices were placed on slides,
and then kept frozen at -20°C until staining. Alternating
brain slices were then thawed briefly and stained with
cresyl violet (Sigma, St. Louis, Missouri), cover slipped
with Permount (Fisher Scientific, Pittsburgh, PA) and
were visualized with either an Olympus microscope or a
Zeiss AxioImager microscope (for brightfield Z-stack
images).
Cell Nuclei Count Analysis
Cell nuclei counts were performed in the cerebellum
(using brightfield z-stack microscopy) in order to quan-
tify differences in cell nuclei number. This was done
using brightfield Z-stack images of the granule cell layer
of the cerebellum in cresyl violet stained tissue. A rec-
tangular counting area was drawn on the Z-stack images
using Axiovision software. This demarcated area carried
through the entire Z-stack. Calculating the distance
between the top and bottom slices of the stack in con-
junction with the demarcated area allowed for a volume
measurement to be made. All cell nuclei counts were
done in a total volume of 80 mm3. Using this counting
method, nuclei were clear and easily distinguishable
from each other. Triplicate cell counts were performed
in each region of the cerebellar granule cell layer from
WT and MeCP2 A140V mice. The mean, standard
deviation and p values were calculated using GraphPad
InStat3 software.
Histology: Golgi-Cox Staining of Brain Tissue
The Rapid Golgi-Cox staining kit (FD Neurotechnologies,
Ellicott City, Maryland) was used for staining whole mouse
brains. Mice were euthanized by overdose of isofluorane
and the brains removed. After rinsing in de-ionized water
the brains were incubated for 2 weeks in a Solution A/B
mixture (impregnation) following the manufacturer’s pro-
tocol. The brains were then moved to Solution C (cryopro-
tection) for 4-5 days and subsequently frozen in an
isopentane/dry ice bath. The brains were immediately sec-
tioned into 100-200 μm slices using a cryostat and the
slices were mounted on gelatin-coated slides. After being
allowed to dry for 3-5 days, the staining protocol for devel-
opment of the black precipitate was completed using kit
reagents. The tissue was counterstained with cresyl violet
(Sigma, St. Louis, Missouri). Cover slips were mounted
using Permount (Fisher Scientific, Pittsburgh, Pennsylva-
nia) and slides were visualized using a Zeiss AxioImager
microscope capable of brightfield Z-stack.
Scholl Analysis
Scholl analysis [46] was adapted for use on brightfield
Z-stack images using Axiovision software. Concentric
circles (Scholl lines) were drawn at 20 μm increments
from the center of the cell body. The Scholl lines were
superimposed on the entire stack of images allowing the
analysis to be conducted in a 3-dimensional fashion.
The dendritic arbor was followed through the Z-stack
and the number of intersections made by dendrites with
the Scholl lines was measured as each dendrite traveled
away from the cell body. The Z-stack image slices were
separated by a depth of only 0.280 μm preventing inter-
sections from being missed.
The apical and basal arbors of 10 neurons from a
MeCP2 A140V mouse and 10 neurons from a WT
mouse were captured in Z-stack images. All neurons
were layer II/III pyramidal neurons of similar morphol-
ogy, located in the somatosensory cortex at similar coor-
dinates [56]. Scholl lines were placed on the images
every 20 μm until no more dendrites crossed the Scholl
lines. Axiovision software was then used to manually
mark crossings of each Scholl line by the dendrites of
the neurons. Crossings at each Scholl line were summed
and the mean and standard deviation calculated. p
values comparing the wild type and A140V mouse neu-
rons at each Scholl line were then determined. Graph-
Pad InStat3 software was used for statistical analysis.
Immunohistochemistry
Brain tissue from WT and A140V mutant mice was fro-
zen in an isopentane/dry ice bath and 10 μm frozen
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sections were cut on a cryostat, placed on slides, and
frozen at -20°C until staining. Tissue was then fixed
with 4% PFA, blocked and permeabilized with a mixture
of 10% goat serum, 1% BSA, and 0.2% Triton X100, and
incubated overnight at 4°C with anti-MeCP2 antibody
(PA1-888 rabbit anti-MeCP2 antibody, Affinity BioRea-
gents, Rockford, Illinois). This is a polyclonal antibody
that recognizes the C-terminus of the MeCP2 protein.
Sections were then incubated with secondary antibody
(Alexa Fluor 488 goat anti-rabbit antibody, Invitrogen,
Carlsbad, California) for 2 hours at room temperature.
Following a wash step, sections were coverslipped with
Pro-long Gold (Invitrogen, Carlsbad, California) mount-
ing medium. MeCP2 staining in the slices was visualized
using a Zeiss confocal microscope.
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